INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
– 2.4 g/dL mean increase in hemoglobin at 24 weeks – – Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis – -  Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa. , Dec. 09, 2019 (GLOBE NEWSWIRE) --   Achillion
View HTML
Toggle Summary European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor
– Phase 3 PNH initiation planned early 2020 – BLUE BELL, Pa. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today
View HTML
Toggle Summary Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
BLUE BELL, Pa. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S.
View HTML
Toggle Summary Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Reached an agreement to be acquired by Alexion;  transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2 combination trial top-line results to be presented at 61st ASH Annual Meeting – – ACH-5228 Phase 1
View HTML
Toggle Summary Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting
BLUE BELL, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the acceptance of two abstracts about
View HTML
Toggle Summary Alexion to Acquire Achillion
- Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for
View HTML
Toggle Summary Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
BLUE BELL, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
View HTML
Toggle Summary Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 – – Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the
View HTML
Toggle Summary Achillion to Present at the Baird 2019 Global Healthcare Conference
BLUE BELL, Pa. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
View HTML
Toggle Summary Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near complete and sustained inhibition of the alternative pathway and its tolerability
View HTML